Pharmacotherapy of cerebral ischemia

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2009-07-20

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656560903055095PMID 19514865
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.

  2013cited by this paper
• Multifunctional actions of approved and candidate stroke drugs

  2011cited by this paper
• Clinical trials for cytoprotection in stroke

  2011cited by this paper
• Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2009cited by this paper
• Methodological Quality of Animal Studies of Neuroprotective Agents Currently in Phase II/III Acute Ischemic Stroke Trials

  2009influential reference
• Acute ischemic stroke: Imaging-guided tenecteplase treatment in an extended time window

  2009cited by this paper
• Albumin ameliorates tissue plasminogen activator-mediated blood–brain barrier permeability and ischemic brain injury in rats

  2009cited by this paper
• Acute ischemic stroke

  2009cited by this paper
• Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study.

  2009cited by this paper
• Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

  2009cited by this paper
• Current status of neuroprotection for cerebral ischemia: synoptic overview.

  2009influential reference
• Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of an International Phase III Trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II)

  2008cited by this paper
• Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke.

  2008cited by this paper
• Mechanical endovascular acute stroke treatment: here to stay

  2008cited by this paper
• Is it time to definitely abandon neuroprotection in acute ischemic stroke?

  2008cited by this paper
• Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial (EPITHET): a placebo-controlled randomised trial.

  2008cited by this paper
• NXY-059 for the Treatment of Acute Stroke: Pooled Analysis of the SAINT I and II Trials

  2008cited by this paper
• The Role of Thrombolysis in Acute Ischemic Stroke

  2008cited by this paper
• Anticoagulants for acute ischaemic stroke.

  2008cited by this paper
• Activation of PDGF-CC by tissue plasminogen activator impairs blood-brain barrier integrity during ischemic stroke

  2008cited by this paper
• Intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: an update

  2008cited by this paper
• The Combined Approach to Lysis Utilizing Eptifibatide and rt-PA in Acute Ischemic Stroke: The CLEAR Stroke Trial

  2008cited by this paper
• Major ongoing stroke trials.

  2008cited by this paper
• The Interventional Management of Stroke (IMS) II Study

  2007cited by this paper
• Is Intra-Arterial Thrombolysis Safe After Full-Dose Intravenous Recombinant Tissue Plasminogen Activator for Acute Ischemic Stroke?

  2007cited by this paper
• The Interventional Management of Stroke (IMS) II Study.

  2007cited by this paper
• Dihydropyridine Calcium Antagonists Increase Fibrinolytic Activity: A Systematic Review

  2007cited by this paper
• Long-term outcome after thrombolysis in telemedical stroke care

  2007cited by this paper
• Erythropoietin-Induced Neurovascular Protection, Angiogenesis, and Cerebral Blood Flow Restoration after Focal Ischemia in Mice

  2007cited by this paper
• Microvascular Thrombosis : A Two-Photon Laser-Scanning Microscopy Study Albumin Therapy Improves Local Vascular Dynamics in a Rat Model of Primary

  2007cited by this paper
• Antiedema Therapy in Ischemic Stroke

  2007cited by this paper
• Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

  2007cited by this paper
• Molecular mechanisms underlying neuroprotective effects of albumin after ischemic stroke.

  2007cited by this paper
• Life After Cerovive: A Personal Perspective on Ischemic Neuroprotection in the Post–NXY-059 Era

  2007cited by this paper
• Major ongoing stroke trials.

  2006cited by this paper
• Intravenous ancrod for acute ischaemic stroke in the European Stroke Treatment with Ancrod Trial: a randomised controlled trial.

  2006cited by this paper
• Dose Escalation of Desmoteplase for Acute Ischemic Stroke (DEDAS): Evidence of Safety and Efficacy 3 to 9 Hours After Stroke Onset

  2006cited by this paper
• The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke—I: Physiological Responses and Safety Results

  2006cited by this paper
• Intrinsic and extrinsic erythropoietin enhances neuroprotection against ischemia and reperfusion injury in vitro

  2006cited by this paper
• 1,026 Experimental treatments in acute stroke

  2006cited by this paper
• Tissue-type plasminogen activator: a multifaceted modulator of neurotransmission and synaptic plasticity.

  2006cited by this paper
• The ALIAS Pilot Trial: A Dose-Escalation and Safety Study of Albumin Therapy for Acute Ischemic Stroke—II: Neurologic Outcome and Efficacy Analysis

  2006cited by this paper
• Magnetic resonance imaging profiles predict clinical response to early reperfusion: The diffusion and perfusion imaging evaluation for understanding stroke evolution (DEFUSE) study

  2006cited by this paper
• Experimental Treatments in Acute Stroke

  2006cited by this paper
• Outcome and Symptomatic Bleeding Complications of Intravenous Thrombolysis Within 6 Hours in MRI-Selected Stroke Patients: Comparison of a German Multicenter Study With the Pooled Data of ATLANTIS, ECASS, and NINDS tPA Trials

  2006cited by this paper
• On the Analysis and Interpretation of Outcome Measures in Stroke Clinical Trials: Lessons From the SAINT I Study of NXY-059 for Acute Ischemic Stroke

  2006cited by this paper
• Comparison of Tissue Plasminogen Activator Administration Management Between Telestroke Network Hospitals and Academic Stroke Centers: The Telemedical Pilot Project for Integrative Stroke Care in Bavaria/Germany

  2006cited by this paper
• NXY-059 for acute ischemic stroke.

  2006cited by this paper
• Argatroban tPA stroke study: study design and results in the first treated cohort.

  2006cited by this paper
• NXY-059 for acute ischemic stroke.

  2006cited by this paper
• Docosahexaenoic Acid Complexed to Albumin Elicits High-Grade Ischemic Neuroprotection

  2005cited by this paper
• The Desmoteplase in Acute Ischemic Stroke Trial (DIAS): A Phase II MRI-Based 9-Hour Window Acute Stroke Thrombolysis Trial With Intravenous Desmoteplase

  2005cited by this paper
• Cost of stroke in Europe

  2005cited by this paper
• The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19 435 patients with acute ischaemic stroke

  2005cited by this paper
• Vampire Bat Salivary Plasminogen Activator (Desmoteplase) Inhibits Tissue-Type Plasminogen Activator-Induced Potentiation of Excitotoxic Injury

  2005cited by this paper
• CAST: randomised placebo-controlled trial of early aspirin use in 20 000 patients with acute ischaemic stroke

  2005cited by this paper
• Stroke Units, Tissue Plasminogen Activator, Aspirin and Neuroprotection: Which Stroke Intervention Could Provide the Greatest Community Benefit?

  2005cited by this paper
• Emergency Administration of Abciximab for Treatment of Patients With Acute Ischemic Stroke: Results of a Randomized Phase 2 Trial

  2005cited by this paper
• Anticoagulants for Acute Ischemic Stroke

  2004cited by this paper
• Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials.

  2004cited by this paper
• Erythropoietin mediates tissue protection through an erythropoietin and common beta-subunit heteroreceptor.

  2004cited by this paper
• Prehospital Neuroprotective Therapy for Acute Stroke: Results of the Field Administration of Stroke Therapy–Magnesium (FAST–MAG) Pilot Trial

  2004cited by this paper
• Combined Intravenous and Intra-Arterial Recanalization for Acute Ischemic Stroke: The Interventional Management of Stroke Study

  2004cited by this paper
• Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial.

  2004cited by this paper
• Treatment of Stroke With Erythropoietin Enhances Neurogenesis and Angiogenesis and Improves Neurological Function in Rats

  2004cited by this paper
• Mannitol Use in Acute Stroke: Case Fatality at 30 Days and 1 Year

  2003cited by this paper
• Vampire Bat Salivary Plasminogen Activator (Desmoteplase): A Unique Fibrinolytic Enzyme That Does Not Promote Neurodegeneration

  2003cited by this paper
• Erythropoietin Selectively Attenuates Cytokine Production and Inflammation in Cerebral Ischemia by Targeting Neuronal Apoptosis

  2003cited by this paper
• Excitatory amino acid antagonists for acute stroke.

  2003cited by this paper
• Effect of Intravenous Thrombolysis on MRI Parameters and Functional Outcome in Acute Stroke <6 Hours

  2002cited by this paper
• Albumin Therapy of Transient Focal Cerebral Ischemia: In Vivo Analysis of Dynamic Microvascular Responses

  2002cited by this paper
• Effects of magnesium sulfate on energy metabolites and glutamate in the cortex during focal cerebral ischemia and reperfusion in the gerbil monitored by a dual-probe microdialysis technique.

  2002cited by this paper
• Oral Citicoline in Acute Ischemic Stroke: An Individual Patient Data Pooling Analysis of Clinical Trials

  2002cited by this paper
• Systemic fatty acid responses to transient focal cerebral ischemia: influence of neuroprotectant therapy with human albumin

  2002cited by this paper
• Erythropoietin Is a Paracrine Mediator of Ischemic Tolerance in the Brain: Evidence from an In Vitro Model

  2002cited by this paper
• Erythropoietin Therapy for Acute Stroke Is Both Safe and Beneficial

  2002cited by this paper
• Aggressive Mechanical Clot Disruption and Low-dose Intra-arterial Third-generation Thrombolytic Agent for Ischemic Stroke: A Prospective Study

  2002cited by this paper
• Erythropoietin and erythropoietin receptor in human ischemic/hypoxic brain

  2001cited by this paper
• Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress

  2001cited by this paper
• Effects of Citicoline on Phospholipid and Glutathione Levels in Transient Cerebral Ischemia

  2001cited by this paper
• Risk Factors for Severe Hemorrhagic Transformation in Ischemic Stroke Patients Treated With Recombinant Tissue Plasminogen Activator: A Secondary Analysis of the European-Australasian Acute Stroke Study (ECASS II)

  2001cited by this paper
• Human Albumin Therapy of Acute Ischemic Stroke: Marked Neuroprotective Efficacy at Moderate Doses and With a Broad Therapeutic Window

  2001cited by this paper
• A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients

  2001cited by this paper
• Neuroprotective effect of treatment with human albumin in permanent focal cerebral ischemia: histopathology and cortical perfusion studies.

  2001cited by this paper
• The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling

  2001cited by this paper
• Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial.

  2000cited by this paper
• Effect of citicoline on ischemic lesions as measured by diffusion-weighted magnetic resonance imaging. Citicoline 010 Investigators.

  2000cited by this paper
• Indications for early aspirin use in acute ischemic stroke : A combined analysis of 40 000 randomized patients from the chinese acute stroke trial and the international stroke trial. On behalf of the CAST and IST collaborative groups.

  2000cited by this paper
• Effect of citicoline on ischemic lesions as measured by diffusion‐weighted magnetic resonance imaging

  2000cited by this paper
• The rtPA (alteplase) 0- to 6-hour acute stroke trial, part A (A0276g) : results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators.

  2000cited by this paper
• Indications for Early Aspirin Use in Acute Ischemic Stroke

  2000cited by this paper
• A randomized efficacy trial of citicoline in patients with acute ischemic stroke.

  1999cited by this paper
• Recommendations for standards regarding preclinical neuroprotective and restorative drug development.

  1999cited by this paper
• Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke.

  1999cited by this paper
• Pathophysiological topography of acute ischemia by combined diffusion-weighted and perfusion MRI.

  1999cited by this paper
• Intra-arterial Prourokinase for Acute Ischemic Stroke: The PROACT II Study: A Randomized Controlled Trial

  1999cited by this paper
• Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism.

  1999cited by this paper
• Choline deficiency‐induced apoptosis in PC12 cells is associated with diminished membrane phosphatidylcholine and sphingomyelin, accumulation of ceramide and diacylglycerol, and activation of a caspase

  1999cited by this paper
• Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke: Emergency Management of Stroke (EMS) Bridging Trial.

  1999cited by this paper
• Prediction of stroke outcome with echoplanar perfusion- and diffusion-weighted MRI

  1998cited by this paper

• Citicoline: pharmacological and clinical review, 2022 update

  2022cites this paper
• P2 receptor interaction and signalling cascades in neuroprotection.

  2019cites this paper
• Inhibition of Connexin43 hemichannels with Gap19 protects cerebral ischemia/reperfusion injury via the JAK2/STAT3 pathway in mice.

  2019cites this paper
• Reframing the Biological Basis of Neuroprotection Using Functional Genomics: Differentially Weighted, Time-Dependent Multifactor Pathogenesis of Human Ischemic Brain Damage

  2018cites this paper
• Current and future perspectives on the treatment of cerebral ischemia

  2017influential citation
• Dehydroascorbic acid for the treatment of acute ischemic stroke.

  2016cites this paper
• [General anesthetics as a factor of effective neuroprotection in ischemic stroke models].

  2015cites this paper
• La barrière hémato-encéphalique lors de l’ischémie cérébrale : une cible thérapeutique

  2012cites this paper
• [Dysfunction of the blood-brain barrier during ischaemia: a therapeutic concern].

  2012cites this paper
• Endothelial Cells and Astrocytes: A Concerto en Duo in Ischemic Pathophysiology

  2012cites this paper
• Citicoline: pharmacological and clinical review, 2010 update.

  2011cites this paper
• Citicolina: revisión farmacológica y clínica, actualización 2010

  2011cites this paper
• Therapeutic Targets for Neuroprotection in Acute Ischemic Stroke: Lost in Translation?

  2011cites this paper
• Preclinical Evaluation of Postischemic Dehydroascorbic Acid Administration in a Large-Animal Stroke Model

  2011cites this paper
• A role for growth hormone in neurorestoration and neurogenic processes in the brain

  2010influential citation
• The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia.

  2009cites this paper